Zinc supplementation in cirrhotic patients

The effect of zinc supplementation on clinical situation and biochemical markers in cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106122017N4

Enrollment

Registered

2011-09-07

Start date

2006-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Failure. Chronic hepatic failure

Interventions

Intervention 1: Interventional group: Zinc Sulfate Capsule , 50 mg daily, oral for three months. Intervention 2: The control group: starch coated Capsule, daily for three months.

Treatment - Drugs

Placebo

Interventional group: Zinc Sulfate Capsule , 50 mg daily, oral for three months

The control group: starch coated Capsule, daily for three months

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:age more than 18 years and suffering from cirrhosis. Exclusion criteria: hepato cellular carcinoma; use of Aldacton or other diuretics over than 50 mg daily; use of anabolic hormones; diuretics or Alb (in recent one month); sever renal or respiratory disorders; pregnancy and lactation; Diabetes mellitus; liver transplantation during the study period and patients with clinical evidence of ascites

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Child-Pugh score. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: Numeral, calculates with severity of Ascitis, total bilirubin, INR, albumin , severity of Encephalopathy.;Serum Zinc level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: µg/dl.;Copper level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: µg/dl.;Iron level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: µg/dl.;Albumin level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: gr/dl.;BUN. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: mg/dl.;Creatinin. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: mg/dl.	—

Measure

Time frame

Child-Pugh score. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: Numeral, calculates with severity of Ascitis, total bilirubin, INR, albumin , severity of Encephalopathy.;Serum Zinc level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: µg/dl.;Copper level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: µg/dl.;Iron level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: µg/dl.;Albumin level. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: gr/dl.;BUN. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: mg/dl.;Creatinin. Timepoint: At the first day and the end of 90th day of interventional period. Method of measurement: mg/dl.

—

Secondary

Measure	Time frame
Clinical and lab test. Timepoint: Three month after intervention. Method of measurement: Clinical and laboratory tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParisa Rezaeifar, MD

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences

prezaeifar@gmail.com+98 41 1336 7473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 25, 2026